

**POLICY:** Hyperlipidemia – Leqvio Utilization Management Medical Policy

- Leqvio<sup>®</sup> (inclisiran subcutaneous injection – Novartis)

**EFFECTIVE DATE:** 6/1/2022**LAST REVISION DATE:** 04/26/2023; selected revision 08/30/2023**COVERAGE CRITERIA FOR:** All UCare Plans

---

**OVERVIEW**

Leqvio, a small interfering ribonucleic acid (RNA) directed to proprotein convertase subtilisin kexin type 9 (PCSK9) messenger RNA, is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).<sup>1</sup> The safety and effectiveness have not been established in pediatric patients.

**Dosing Information**

Leqvio is given as a subcutaneous injection and should be administered by a healthcare professional. The dose is 284 mg given as a single subcutaneous injection initially, again at 3 months, and then once every 6 months.

**Guidelines**

Many guidelines are available regarding the treatment of patients with dyslipidemia which include the management of HeFH and atherosclerotic cardiovascular disease (ASCVD).<sup>2-10</sup> For patients with elevated LDL-C, statins are the cornerstone of therapy and recommended first-line to be used at maximally tolerated doses due to the established benefits regarding the reduction of cardiovascular (CV) risks. Atorvastatin 40 mg to 80 mg once daily (QD) and rosuvastatin 20 mg to 40 mg QD are considered high-intensity statins as they achieve LDL-C lowering of  $\geq 50\%$ .

- **The American College of Cardiology (ACC) Expert Consensus Decision Pathway on the Role of Non-Statin Therapies** for LDL-C Lowering in the Management of ASCVD Risk (2022) make several recommendations regarding PCSK9 inhibitors and Leqvio.<sup>2</sup> For adults with clinical ASCVD at very high risk (e.g., patients with major ASCVD events, HeFH, diabetes) who are on statin therapy for secondary prevention, the general goal is  $\geq 50\%$  LDL-C reduction and an LDL-C  $< 55$  mg/dL with maximally tolerated statin therapy. If the above goals are not achieved, the initial non-statin agents recommended include ezetimibe and/or a PCSK9 monoclonal antibody (i.e., Repatha<sup>®</sup> [evolocumab subcutaneous injection] or Praluent<sup>®</sup> [alirocumab subcutaneous injection]). Leqvio may also be considered.
- **The American Heart Association (AHA)/ACC guidelines for chronic coronary disease (2023)** state that in patients with chronic coronary disease on maximally tolerated statin therapy who have an LDL-C level  $\geq 70$  mg/dL, and in whom ezetimibe and PCSK9 inhibitors are deemed insufficient or not tolerated, it may be reasonable to add Nexletol<sup>®</sup> (bempedoic acid tablets) or Leqvio (in place of a PCSK9 inhibitor) to further reduce LDL-C levels.<sup>10</sup>
- **The AHA** published a scientific statement regarding familial hypercholesterolemia (2015).<sup>8</sup> Key points are that the condition may start early (in childhood or adolescence) and is noted by LDL-C levels  $\geq 190$  mg/dL. Premature CV disease can result. Diagnosis can be confirmed by genetic testing. The Dutch Lipid Clinic Network criteria and Simon Broome criteria may also be used

which incorporate cholesterol levels, family history, clinical findings, and physical manifestations. Aggressive lipid-lowering therapy is recommended to achieve LDL-C reductions of at least 50%.

#### **POLICY STATEMENT**

Prior Authorization is recommended for medical benefit coverage of Leqvio. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indications. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Leqvio as well as the monitoring required for adverse events and long-term efficacy, approval requires Leqvio to be prescribed by or in consultation with a physician who specializes in the condition being treated. A patient who has previously met Initial Therapy criteria for Leqvio for the requested indication under the Coverage Review Department and is currently receiving Leqvio is only required to meet continuation of therapy criteria (i.e., currently receiving therapy). If past criteria have not been met under the Coverage Review Department and the patient is currently receiving Leqvio, or is restarting Leqvio, Initial Therapy criteria must be met.

**Automation:** None.

#### **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of Leqvio is recommended in those who meet one of the following criteria:

#### **FDA-Approved Indications**

- 
- 2. Heterozygous Familial Hypercholesterolemia (HeFH).\*** Approve for 1 year if the patient meets ONE of the following (A or B):
- A) Initial Therapy.** Approve if the patient meets all of the following (i, ii, iii, and iv):
- i.** Patient is  $\geq 18$  years of age; **AND**
  - ii.** Patient meets one of the following (a, b, or c):
    - a)** Patient has an untreated low-density lipoprotein cholesterol (LDL-C) level  $\geq 190$  mg/dL (prior to treatment with antihyperlipidemic agents); **OR**
    - b)** Patient has genetic confirmation of heterozygous familial hypercholesterolemia by mutations in the low-density lipoprotein receptor, apolipoprotein B, proprotein convertase subtilisin kexin type 9, or low-density lipoprotein receptor adaptor protein 1 gene; **OR**
    - c)** Patient has been diagnosed with heterozygous familial hypercholesterolemia meeting one of the following diagnostic criteria thresholds [(1) or (2)]:
      - (1)** Prescribing physician confirms that the Dutch Lipid Network criteria score was  $> 5$ ; **OR**
      - (2)** Prescribing physician confirms that Simone Broome criteria met the threshold for “definite” or “possible (or probable)” familial hypercholesterolemia; **AND**
  - iii.** Patient meets one of the following (a or b):
    - a)** Patient meets all of the following [(1), (2), and (3)]:
      - (1)** Patient has tried one high-intensity statin therapy (i.e., atorvastatin  $\geq 40$  mg daily; rosuvastatin  $\geq 20$  mg daily [as a single entity or as a combination product]); **AND**
      - (2)** Patient has tried one high-intensity statin along with ezetimibe (as a single-entity or as a combination product) for  $\geq 8$  continuous weeks; **AND**
      - (3)** LDL-C level after this treatment regimen remains  $\geq 70$  mg/dL; **OR**
    - b)** Patient has been determined to be statin intolerant by meeting one of the following [(1) or (2)]:

- (1) Patient experienced statin-related rhabdomyolysis; OR  
Note: Rhabdomyolysis is statin-induced muscle breakdown that is associated with markedly elevated creatine kinase levels (at least 10 times the upper limit of normal), along with evidence of end organ damage which can include signs of acute renal injury (noted by substantial increases in serum creatinine [Scr] levels [ $a \geq 0.5$  mg/dL increase in Scr or doubling of the Scr] and/or myoglobinuria [myoglobin present in urine]).
  - (2) Patient meets all of the following [(a), (b), and (c)]:
    - (a) Patient experienced skeletal-related muscle symptoms; AND  
Note: Examples of skeletal-related muscle symptoms include myopathy (muscle weakness) or myalgia (muscle aches, soreness, stiffness, or tenderness).
    - (b) The skeletal-muscle related symptoms occurred while receiving separate trials of both atorvastatin and rosuvastatin (as single-entity or combination products); AND
    - (c) When receiving separate trials of both atorvastatin and rosuvastatin (as single-entity or as combination products) the skeletal-related muscle symptoms resolved upon discontinuation of each respective statin therapy (atorvastatin and rosuvastatin); AND  
Note: Examples of skeletal-related muscle symptoms include myopathy and myalgia.
  - iv. Medication is prescribed by or in consultation with a cardiologist, an endocrinologist, or a physician who focuses in the treatment of cardiovascular risk management and/or lipid disorders; OR
  - B) Patient Currently Receiving Leqvio. Approve if according to the prescribing physician, the patient has experienced a response to therapy.  
Note: Examples of a response to therapy include decreasing LDL-C, total cholesterol, non-high-density lipoprotein (non-HDL-C), or apolipoprotein B levels. Also, if the patient is currently receiving the requested therapy but has not previously received approval of Leqvio for this specific indication through the Coverage Review Department, review under criteria for Initial Therapy. If the patient is restarting therapy with Leqvio, Initial Therapy criteria must be met.
- Dosing.** Approve ONE of the following dosage regimens (A or B):
- A) Initial dose is 284 mg given as a single subcutaneous injection, again at 3 months, and then once every 6 months; OR
  - B) Maintenance dose is 284 mg given as a subcutaneous injection once every 6 months.

- 
3. **Primary Hyperlipidemia.\*** Approve for 1 year if the patient meets ONE of the following (A or B):  
Note: This is not associated with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) and may be referred to as combined hyperlipidemia, hypercholesterolemia (pure, primary), dyslipidemia, or increased/elevated low-density lipoprotein cholesterol (LDL-C) levels.
- A) Initial Therapy. Approve if the patient meets all of the following (i, ii, iii, and iv):
    - i. Patient is  $\geq 18$  years of age; AND
    - ii. Patient has a coronary artery calcium or calcification score  $\geq 300$  Agatston units; AND
    - iii. Patient meets one of the following (a or b):
      - a) Patient meets all of the following [(1)], (2), and (3)]:
        - (1) Patient has tried one high-intensity statin therapy (i.e., atorvastatin  $\geq 40$  mg daily; rosuvastatin  $\geq 20$  mg daily [as a single-entity or as a combination product]); AND
        - (2) Patient has tried the one high-intensity statin therapy above along with ezetimibe (as a single-entity or as a combination product) for  $\geq 8$  continuous weeks; AND

- (3) LDL-C level after this treatment regimen remains  $\geq 100$  mg/dL; OR
- b) Patient has been determined to be statin intolerant by meeting one of the following [(1) or (2)]:
  - (1) Patient experienced statin-related rhabdomyolysis; OR  
Note: Rhabdomyolysis is statin-induced muscle breakdown that is associated with markedly elevated creatine kinase levels (at least 10 times the upper limit of normal), along with evidence of end organ damage which can include signs of acute renal injury (noted by substantial increases in serum creatinine [Scr] levels [ $a \geq 0.5$  mg/dL increase in Scr or doubling of the Scr] and/or myoglobinuria [myoglobin present in urine]).
  - (2) Patient meets all of the following [(a), (b), and (c)]:
    - (a) Patient experienced skeletal-related muscle symptoms; AND  
Note: Examples of skeletal-related muscle symptoms include myopathy (muscle weakness) or myalgia (muscle aches, soreness, stiffness, or tenderness).
    - (b) The skeletal-muscle related symptoms occurred while receiving separate trials of both atorvastatin and rosuvastatin (as single-entity or combination products); AND
    - (c) When receiving separate trials of both atorvastatin and rosuvastatin (as single-entity or as combination products) the skeletal-related muscle symptoms resolved upon discontinuation of each respective statin therapy (atorvastatin and rosuvastatin); AND  
Note: Examples of skeletal-related muscle symptoms include myopathy and myalgia.
- iv. Medication is prescribed by or in consultation with a cardiologist, an endocrinologist, or a physician who focuses in the treatment of cardiovascular risk management and/or lipid disorders; OR
- B) Patient Currently Receiving Leqvio. Approve if according to the prescribing physician, the patient has experienced a response to therapy.  
Note: Examples of a response to therapy include decreasing LDL-C, total cholesterol, non-high-density lipoprotein (non-HDL-C), or apolipoprotein B levels. Also, if the patient is currently receiving the requested therapy but has not previously received approval of Leqvio for this specific indication through the Coverage Review Department, review under criteria for Initial Therapy. If the patient is restarting therapy with Leqvio, Initial Therapy criteria must be met.

**Dosing.** Approve ONE of the following dosage regimens (A or B):

- A) Initial dose is 284 mg given as a single subcutaneous injection, again at 3 months, and then once every 6 months; OR
- B) Maintenance dose is 284 mg given as a subcutaneous injection once every 6 months.

### Other Uses with Supportive Evidence

- 1. **Atherosclerotic Cardiovascular Disease.\*** Approve for 1 year if the patient meets ONE of the following (A or B):
  - A) Initial Therapy. Approve if the patient meets all of the following (i, ii, iii, and iv):
    - i. Patient is  $\geq 18$  years of age; AND
    - ii. Patient has had one of the following conditions or diagnoses (a, b, c, d, e, or f):
      - a) A previous myocardial infarction or a history of an acute coronary syndrome; OR
      - b) Angina (stable or unstable); OR
      - c) A past history of stroke or transient ischemic attack; OR
      - d) Coronary artery disease; OR

- e) Peripheral arterial disease; OR
- f) Patient has undergone a coronary or other arterial revascularization procedure in the past;  
AND  
Note: Examples include coronary artery bypass graft surgery, percutaneous coronary intervention, angioplasty, and coronary stent procedures.
- iii. Patient meets one of the following (a or b):
  - a) Patient meets all of the following [(1), (2), and (3)]:
    - (1) Patient has tried one high-intensity statin therapy (i.e., atorvastatin  $\geq$  40 mg daily; rosuvastatin  $\geq$  20 mg daily [as a single entity or as a combination product]); AND
    - (2) Patient has tried one high-intensity statin along with ezetimibe (as a single-entity or as a combination product) for  $\geq$  8 continuous weeks; AND
    - (3) Low-density lipoprotein cholesterol (LDL-C) level after this treatment regimen remains  $\geq$  70 mg/dL; OR
  - b) Patient has been determined to be statin intolerant by meeting one of the following [(1) or (2)]:
    - (1) Patient experienced statin-related rhabdomyolysis; OR  
Note: Rhabdomyolysis is statin-induced muscle breakdown that is associated with markedly elevated creatine kinase levels (at least 10 times the upper limit of normal), along with evidence of end organ damage which can include signs of acute renal injury (noted by substantial increases in serum creatinine [Scr] levels [ $a \geq 0.5$  mg/dL increase in Scr or doubling of the Scr] and/or myoglobinuria [myoglobin present in urine]).
    - (2) Patient meets all of the following [(a), (b), and (c)]:
      - (a) Patient experienced skeletal-related muscle symptoms; AND  
Note: Examples of skeletal-related muscle symptoms include myopathy (muscle weakness) or myalgia (muscle aches, soreness, stiffness, or tenderness).
      - (b) The skeletal-muscle related symptoms occurred while receiving separate trials of both atorvastatin and rosuvastatin (as single-entity or combination products); AND
      - (c) When receiving separate trials of both atorvastatin and rosuvastatin (as single-entity or as combination products) the skeletal-related muscle symptoms resolved upon discontinuation of each respective statin therapy (atorvastatin and rosuvastatin); AND  
Note: Examples of skeletal-related muscle symptoms include myopathy and myalgia.
- iv. Medication is prescribed by or in consultation with a cardiologist, an endocrinologist, or a physician who focuses in the treatment of cardiovascular risk management and/or lipid disorders; OR
- B) Patient Currently Receiving Leqvio. Approve if according to the prescribing physician, the patient has experienced a response to therapy.  
Note: Examples of a response to therapy include decreasing LDL-C, total cholesterol, non-high-density lipoprotein (non-HDL-C), or apolipoprotein B levels. Also, if the patient is currently receiving the requested therapy but has not previously received approval of Leqvio for this specific indication through the Coverage Review Department, review under criteria for Initial Therapy. If the patient is restarting therapy with Leqvio, Initial Therapy criteria must be met.

**Dosing.** Approve ONE of the following dosage regimens (A or B):

- A) Initial dose is 284 mg given as a single subcutaneous injection, again at 3 months, and then once every 6 months; OR
- B) Maintenance dose is 284 mg given as a subcutaneous injection once every 6 months.

**Note:**

\* A patient may have a diagnoses that pertains to more than one indication, therefore, consider review under different approval conditions, if applicable (e.g., a patient with heterozygous familial hypercholesterolemia may have had a clinical ASCVD event, a patient with primary hyperlipidemia may have heterozygous familial hypercholesterolemia).

---

**CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Coverage of Leqvio is not recommended in the following situations:

1. **Concurrent use of Leqvio with Repatha (evolocumab subcutaneous injection) or Praluent (alirocumab subcutaneous injection).** Repatha and Praluent are PCSK9 inhibitors and should not be used with Leqvio due to a similar mechanism of action.<sup>1</sup> Patients receiving PCSK9 inhibitors were excluded from the pivotal trials with Leqvio.
2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

**REFERENCES**

1. Leqvio<sup>®</sup> subcutaneous injection [prescribing information]. East Hanover, NJ: Novartis; July 2023.
2. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. *J Am Coll Cardiol*. 2022;80(14):1366-1418.
3. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. *Circulation*. 2014;129(25 Suppl 2):S1-S45.
4. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082-e1143.
5. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2020;105(12):3613-3682.
6. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-full report. *J Clin Lipidol*. 2015;9:129-169.
7. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. *J Clin Lipidol*. 2011;5:S1-S8.
8. Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia. A scientific statement from the American Heart Association. *Circulation*. 2015;132(22):2167-2192.
9. Haase A, Goldberg AC. Identification of people with heterozygous familial hypercholesterolemia. *Curr Opin Lipidol*. 2012;23:282-289.
10. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2023 July 14. [Online ahead of print].



## HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	01/03/2022
Early Annual Revision	No criteria changes. The header of the policy was changed from “Hyperlipidemia” to “Proprotein Convertase Subtilisin Kexin Type 9 Related Products.”	04/13/2022
Annual Revision	<p>It was added to the Policy Statement that a patient who has previously met initial therapy criteria for Leqvio for the requested indication under the Coverage Review Department and is currently receiving Leqvio is only required to meet continuation of therapy criteria (i.e., currently receiving therapy). If past criteria have not been met under the Coverage Review Department and the patient is currently receiving Leqvio, or is restarting Leqvio, initial criteria must be met. In addition, the following changes were made:</p> <p><b>Atherosclerotic Cardiovascular Disease:</b> Requirements were divided to distinguish between initial therapy and patient currently receiving Leqvio (previously there was only one criteria set). For a patient who is currently receiving Leqvio and has previously met initial therapy criteria for the requested indication under the Coverage Review Department, only the continuation of therapy criteria has to be met. The continuation of therapy criteria states that according to the prescribing physician, the patient has experienced a response to therapy with examples provided in a Note.</p> <p><b>Heterozygous Familial Hypercholesterolemia:</b> Requirements were divided to distinguish between initial therapy and patient currently receiving Leqvio (previously there was only one criteria set). The criteria to confirm the diagnosis of heterozygous familial hypercholesterolemia were reworded regarding the use of the Dutch Lipid Network criteria and the Simon Broome criteria; also, the phrase “prescriber used” was changed to “the prescribing physician confirms”. For a patient who is currently receiving Leqvio and has previously met initial therapy criteria for the requested indication under the Coverage Review Department, only the continuation of therapy criteria has to be met. The continuation of therapy criteria states that according to the prescribing physician, the patient has experienced a response to therapy with examples provided in a Note.</p>	04/26/2023
Selected Revision	<p><b>Atherosclerotic Cardiovascular Disease:</b> The condition was moved from FDA-Approved Indications to Other Uses with Supportive Evidence. Also, coronary artery disease was added as a condition or diagnosis that represents this indication of use in this related requirement. A Note was added that a patient may have a diagnoses that pertains to more than one indication, therefore, consider review under different approval conditions, if applicable.</p> <p><b>Heterozygous Familial Hypercholesterolemia:</b> A Note was added that a patient may have a diagnoses that pertains to more than one indication, therefore, consider review under different approval conditions, if applicable.</p> <p><b>Primary Hyperlipidemia:</b> This was added as a new FDA-approved indication.</p>	08/30/2023

## APPENDIX A

### Simon Broome Register Diagnostic Criteria.<sup>9</sup>

<b>Definite Familial Hypercholesterolemia</b>
Raised cholesterol
--Total cholesterol greater than 6.7 mmol/L (260 mg/dL) or LDL-C > 4.0 mmol/L (155 mg/dL) in a patient < 16 years of age; OR
--Total cholesterol > 7.5 mmol/L (290 mg/dL) or LDL-C > 4.9 mmol/L (190 mg/dL) in a patient > 16 years of age;
<b>AND</b>
--Tendon xanthomas in the patient or in a first (parent, sibling, or child) or second-degree relative (grandparent, aunt, or uncle);
<b>OR</b>
DNA-based evidence of LDL-receptor, familial defective APOB, or PCSK9 mutation.
<b>Possible (or Probable) Familial Hypercholesterolemia</b>
Raised cholesterol
--Total cholesterol greater than 6.7 mmol/L (260 mg/dL) or LDL-C > 4.0 mmol/L (155 mg/dL) in a patient < 16 years of age; OR
--Total cholesterol > 7.5 mmol/L (290 mg/dL) or LDL-C > 4.9 mmol/L (190 mg/dL) in a patient > 16 years of age;
<b>AND</b>
Family history of premature myocardial infarction younger than 50 years of age in second-degree relative or younger than 60 years of age in first-degree relative;
<b>OR</b>
Raised cholesterol
--Total cholesterol greater than 6.7 mmol/L (260 mg/dL) or LDL-C > 4.0 mmol/L (155 mg/dL) in a patient < 16 years of age; OR
--Total cholesterol > 7.5 mmol/L (290 mg/dL) or LDL-C > 4.9 mmol/L (190 mg/dL) in a patient > 16 years of age;
<b>AND</b>
Family history of raised cholesterol > 7.5 mmol (290 mg/dL) in adult first-degree or second-degree relative or > 6.7 mmol/L (260 mg/dL) in child or sibling aged < 16 years.

LDL-C – Low-density lipoprotein cholesterol; LDL – Low-density lipoprotein; APOB – Apolipoprotein B; PCSK9 – Proprotein convertase subtilisin kexin type 9.



## APPENDIX B.

### Dutch Lipid Network Criteria.<sup>8</sup>

Criteria	Score
<b>Family History</b>	
First-degree relative with known premature coronary and/or vascular disease (men < 55 years, women < 60 years)	1
First degree relative with known LDL-C > 95 <sup>th</sup> percentile for age and sex	1
First-degree relative with tendon xanthomata and/or arcus cornealis, OR	2
Patient is < 18 years of age with LDL-C > 95 <sup>th</sup> percentile for age and sex	2
<b>Clinical History</b>	
Patient with premature CAD (age as above)	2
Patient with premature cerebral or peripheral vascular disease (age as above)	1
<b>Physical Examination</b>	
Tendon xanthomas	6
Arcus cornealis at age < 45 years	4
<b>LDL-C</b>	
LDL-C ≥ 8.5 mmol/L (330 mg/dL)	8
LDL-C 6.5 to 8.4 mmol/L (250 to 329 mg/dL)	5
LDL-C 5.0 to 6.4 mmol/L (190 to 249 mg/dL)	3
LDL-C 4.0 to 4.9 mg/dL (155 to 189 mg/dL)	1
<b>DNA Analysis</b>	
Functional mutation LDLR, APOB or PCSK9 gene	8
<b>Stratification</b>	
Definite familial hypercholesterolemia	> 8
Probable familial hypercholesterolemia	6 to 8
Possible familial hypercholesterolemia	3 to 5
Unlikely familial hypercholesterolemia	< 3

LDL-C – Low-density lipoprotein cholesterol; CAD – Coronary artery disease; LDLR – Low-density lipoprotein receptor; APOB – Apolipoprotein B; PCSK9 – Proprotein convertase subtilisin kexin type 9.

## APPENDIX A

### Simon Broome Register Diagnostic Criteria.<sup>9</sup>

<b>Definite Familial Hypercholesterolemia</b>
Raised cholesterol
--Total cholesterol greater than 6.7 mmol/L (260 mg/dL) or LDL-C > 4.0 mmol/L (155 mg/dL) in a patient < 16 years of age; OR
--Total cholesterol > 7.5 mmol/L (290 mg/dL) or LDL-C > 4.9 mmol/L (190 mg/dL) in a patient > 16 years of age;
<b>AND</b>
--Tendon xanthomas in the patient or in a first (parent, sibling, or child) or second-degree relative (grandparent, aunt, or uncle); <b>OR</b>
DNA-based evidence of LDL-receptor, familial defective APOB, or PCSK9 mutation.
<b>Possible (or Probable) Familial Hypercholesterolemia</b>
Raised cholesterol
--Total cholesterol greater than 6.7 mmol/L (260 mg/dL) or LDL-C > 4.0 mmol/L (155 mg/dL) in a patient < 16 years of age; OR
--Total cholesterol > 7.5 mmol/L (290 mg/dL) or LDL-C > 4.9 mmol/L (190 mg/dL) in a patient > 16 years of age;
<b>AND</b>
Family history of premature myocardial infarction younger than 50 years of age in second-degree relative or younger than 60 years of age in first-degree relative;
<b>OR</b>
Raised cholesterol
--Total cholesterol greater than 6.7 mmol/L (260 mg/dL) or LDL-C > 4.0 mmol/L (155 mg/dL) in a patient < 16 years of age; OR

--Total cholesterol > 7.5 mmol/L (290 mg/dL) or LDL-C > 4.9 mmol/L (190 mg/dL) in a patient > 16 years of age;
AND
Family history of raised cholesterol > 7.5 mmol (290 mg/dL) in adult first-degree or second-degree relative or > 6.7 mmol/L (260 mg/dL) in child or sibling aged < 16 years.

LDL-C – Low-density lipoprotein cholesterol; LDL – Low-density lipoprotein; APOB – Apolipoprotein B; PCSK9 – Proprotein convertase subtilisin kexin type 9.

## APPENDIX B.

### Dutch Lipid Network Criteria.<sup>8</sup>

Criteria	Score
<b>Family History</b>	
First-degree relative with known premature coronary and/or vascular disease (men < 55 years, women < 60 years)	1
First degree relative with known LDL-C > 95 <sup>th</sup> percentile for age and sex	1
First-degree relative with tendon xanthomata and/or arcus cornealis, OR	2
Patient is < 18 years of age with LDL-C > 95 <sup>th</sup> percentile for age and sex	2
<b>Clinical History</b>	
Patient with premature CAD (age as above)	2
Patient with premature cerebral or peripheral vascular disease (age as above)	1
<b>Physical Examination</b>	
Tendon xanthomas	6
Arcus cornealis at age < 45 years	4
<b>LDL-C</b>	
LDL-C ≥ 8.5 mmol/L (330 mg/dL)	8
LDL-C 6.5 to 8.4 mmol/L (250 to 329 mg/dL)	5
LDL-C 5.0 to 6.4 mmol/L (190 to 249 mg/dL)	3
LDL-C 4.0 to 4.9 mg/dL (155 to 189 mg/dL)	1
<b>DNA Analysis</b>	
Functional mutation LDLR, APOB or PCSK9 gene	8
<b>Stratification</b>	
Definite familial hypercholesterolemia	> 8
Probable familial hypercholesterolemia	6 to 8
Possible familial hypercholesterolemia	3 to 5
Unlikely familial hypercholesterolemia	< 3

LDL-C – Low-density lipoprotein cholesterol; CAD – Coronary artery disease; LDLR – Low-density lipoprotein receptor; APOB – Apolipoprotein B; PCSK9 – Proprotein convertase subtilisin kexin type 9.